Insider Selling: Danaher (NYSE:DHR) EVP Sells $484,302.00 in Stock

Danaher Corporation (NYSE:DHR) EVP Gregory Milosevich sold 2,100 shares of Danaher stock in a transaction on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $5,158,277.54. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Danaher Price Performance

DHR opened at $232.08 on Friday. The stock’s 50-day moving average price is $222.11 and its 200 day moving average price is $201.53. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a current ratio of 1.63, a quick ratio of 1.29 and a debt-to-equity ratio of 0.45. The firm has a market cap of $163.28 billion, a price-to-earnings ratio of 37.98, a PEG ratio of 2.95 and a beta of 0.76.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The company had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. Danaher’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the business posted $1.89 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 8.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Wednesday, September 30th. Danaher’s dividend payout ratio is currently 26.19%.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Deutsche Bank reissued a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Robert W. Baird upped their target price on shares of Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Wells Fargo & Company reduced their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Monday, October 26th. Finally, DZ Bank cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Eighteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $242.91.

Hedge Funds Weigh In On Danaher

A number of institutional investors and hedge funds have recently modified their holdings of the company. N.F.U. MUTUAL UNIT MANAGERS Ltd purchased a new position in shares of Danaher in the 3rd quarter valued at about $1,144,000. Portland Global Advisors LLC purchased a new stake in Danaher during the third quarter worth approximately $204,000. Cvfg LLC purchased a new stake in Danaher during the third quarter worth approximately $201,000. Bouchey Financial Group Ltd. boosted its holdings in Danaher by 14.3% in the third quarter. Bouchey Financial Group Ltd. now owns 1,662 shares of the conglomerate’s stock valued at $369,000 after purchasing an additional 208 shares in the last quarter. Finally, Benjamin Edwards Inc. boosted its holdings in Danaher by 2.1% in the third quarter. Benjamin Edwards Inc. now owns 20,376 shares of the conglomerate’s stock valued at $4,515,000 after purchasing an additional 416 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.